Candel Therapeutics' CAN-2409 shows durable survival tail in phase 2a advanced NSCLC trial
Candel Therapeutics' CAN-2409 shows durable survival tail in phase 2a advanced NSCLC trial, 50% alive at 24 months
- Extended follow-up from the phase 2a CAN-2409 trial in advanced NSCLC reports outcomes in per-protocol patients.
- Median overall survival reached 25.4 months, roughly double historical outcomes after immune checkpoint inhibitor failure.
- Company plans a precision medicine-based pivotal phase 3 trial in non-squamous NSCLC starting in Q2 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.